CORE LAB REPORTS SECOND QUARTER 2025 RESULTS
- REVENUE OF
$130.2 MILLION , UP 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR - OPERATING INCOME OF
$15.3 MILLION ; EX-ITEMS,$14.5 MILLION , UP OVER 23% SEQUENTIALLY AND DOWN 11% YEAR-OVER-YEAR - OPERATING MARGINS, EX-ITEMS, OF 11%, EXPANDED 160 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF 41%
- GAAP EPS OF
$0.22 ; EX-ITEMS,$0.19 , UP 33% SEQUENTIALLY, AND DOWN 14% YEAR-OVER-YEAR - COMPANY REPURCHASED 237,632 SHARES OF COMMON STOCK, A VALUE OF
$2.7 MILLION - FREE CASH FLOW OF
$10.4 MILLION , UP OVER 160% SEQUENTIALLY - NET DEBT REDUCED BY
$9.1 MILLION ; DEBT LEVERAGE RATIO IMPROVED TO 1.27 - COMPANY ANNOUNCES Q2 2025 QUARTERLY DIVIDEND
Core's CEO,
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of revenue sourced from projects originating outside the
Aligned with Core's strategy to expand its global presence and enhance services in key markets, in the second quarter of 2025, Core Lab opened its new Unconventional Core Analysis Laboratory in
Also in the second quarter of 2025, Core Lab successfully completed a comprehensive analytical program for a major International Oil Company following their first exploration well in the frontier
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
In the second quarter of 2025, Core Lab successfully completed a complex deepwater Plug and Abandonment ("P&A") operation for a client in the
Also in the second quarter of 2025, an operator in
Liquidity, Free Cash Flow, Share Repurchases, and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the second quarter of 2025, cash from operations was
In the second quarter of 2025, Core Lab used a portion of its FCF to repurchase 237,632 shares at an aggregate purchase price of
As of
On
The Company will remain focused on executing its strategic business initiatives. Core Lab will continue to evaluate allocation of capital and other uses of free cash to return value to shareholders, while also reducing debt.
On
On
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, the Company's ROIC for the second quarter of 2025 improved to 9.0%.
Industry and Core Lab Outlook and Guidance
Recent and pending tariffs announced by the
Despite current market volatility, Core maintains its constructive long-term outlook for international upstream activity. The IEA, EIA, and OPEC+ continue to forecast growth in crude oil demand to be between 0.7 and 1.3 million barrels per day in 2025. This demand is primarily driven by non-OECD countries in
Large-scale international oil and gas projects are expected to be less sensitive to near-term volatility of crude oil prices, and Core Lab continues to see steady activity across committed long-cycle projects in the South Atlantic Margin, North and
Activity levels tied to smaller-scale, short-cycle crude oil development projects are expected to remain more sensitive to crude oil price volatility. As a result, changes in crude oil prices are anticipated to have a more immediate impact on drilling and completion activity in the
Core projects Reservoir Description's third quarter revenue to be flat sequentially. Geopolitical conflicts, evolving trade and tariff dynamics, and volatile commodity prices continue to create uncertainty in the demand for laboratory services tied to the maritime transportation and trade of crude oil and derived products.
Turning to Production Enhancement, the
Core Lab believes that the tariff measures under consideration will not apply to the vast majority of service revenue and product sales provided by the Company. Core's services account for over 75% of the Company's total revenue and are currently not subject to tariffs. Core's product sales have been less than 25% of total revenue and are primarily manufactured in the
Reservoir Description's third quarter revenue is projected to range from
Core's third quarter 2025 revenue is projected to range from
The Company's third quarter 2025 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Third quarter guidance assumes an effective tax rate of 25%.
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's second quarter 2025 earnings announcement. The call will begin at
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements Core Lab makes, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the impact on tariffs and sanctions, international markets, international political climates, including the
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com.
CORE LABORATORIES INC. & SUBSIDIARIES | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | % Variance | |||||||||||||||
|
|
| vs. Q1-25 | vs. Q2-24 | ||||||||||||
REVENUE | $ | 130,159 | $ | 123,585 | $ | 130,577 | 5.3 % | (0.3) % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 103,701 | 99,469 | 102,930 | 4.3 % | 0.7 % | |||||||||||
General and administrative expense | 10,464 | 13,647 | 10,259 | (23.3) % | 2.0 % | |||||||||||
Depreciation and amortization | 3,670 | 3,717 | 3,770 | (1.3) % | (2.7) % | |||||||||||
Other (income) expense, net | (2,967) | 2,335 | (2,390) | NM | NM | |||||||||||
Total operating expenses | 114,868 | 119,168 | 114,569 | (3.6) % | 0.3 % | |||||||||||
OPERATING INCOME | 15,291 | 4,417 | 16,008 | 246.2 % | (4.5) % | |||||||||||
Interest expense | 2,711 | 2,602 | 3,209 | 4.2 % | (15.5) % | |||||||||||
Income before income taxes | 12,580 | 1,815 | 12,799 | 593.1 % | (1.7) % | |||||||||||
Income tax expense | 1,911 | 1,746 | 3,609 | 9.5 % | (47.0) % | |||||||||||
Net income | 10,669 | 69 | 9,190 | NM | 16.1 % | |||||||||||
Net income attributable to non- | 33 | 223 | 158 | NM | NM | |||||||||||
Net income (loss) attributable to Core | $ | 10,636 | $ | (154) | $ | 9,032 | NM | 17.8 % | ||||||||
Diluted earnings per share | $ | 0.23 | $ | — | $ | 0.19 | NM | 21.1 % | ||||||||
Diluted earnings (loss) per share | $ | 0.22 | $ | — | $ | 0.19 | NM | 15.8 % | ||||||||
Weighted average common shares | 47,364 | 46,773 | 47,743 | 1.3 % | (0.8) % | |||||||||||
Effective tax rate | 15 | % | 96 | % | 28 | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 86,280 | $ | 80,897 | $ | 86,277 | 6.7 % | — % | ||||||||
Production Enhancement | 43,879 | 42,688 | 44,300 | 2.8 % | (1.0) % | |||||||||||
Consolidated | $ | 130,159 | $ | 123,585 | $ | 130,577 | 5.3 % | (0.3) % | ||||||||
Operating income: | ||||||||||||||||
Reservoir Description | $ | 12,203 | $ | 2,339 | $ | 11,443 | 421.7 % | 6.6 % | ||||||||
Production Enhancement | 3,148 | 1,503 | 4,401 | 109.4 % | (28.5) % | |||||||||||
Corporate and Other | (60) | 575 | 164 | NM | NM | |||||||||||
Consolidated | $ | 15,291 | $ | 4,417 | $ | 16,008 | 246.2 % | (4.5) % | ||||||||
"NM" means not meaningful | ||||||||||||||||
CORE LABORATORIES INC. & SUBSIDIARIES | ||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
(In thousands, except per share data) | ||||||||||
(Unaudited) | ||||||||||
Six Months Ended | % Variance | |||||||||
2025 | 2024 | |||||||||
REVENUE | $ | 253,744 | $ | 260,214 | (2.5) % | |||||
OPERATING EXPENSES: | ||||||||||
Costs of services and product sales | 203,170 | 207,518 | (2.1) % | |||||||
General and administrative expense | 24,111 | 22,048 | 9.4 % | |||||||
Depreciation and amortization | 7,387 | 7,613 | (3.0) % | |||||||
Other (income) expense, net | (632) | (1,544) | NM | |||||||
Total operating expenses | 234,036 | 235,635 | (0.7) % | |||||||
OPERATING INCOME | 19,708 | 24,579 | (19.8) % | |||||||
Interest expense | 5,313 | 6,632 | (19.9) % | |||||||
Income before income taxes | 14,395 | 17,947 | (19.8) % | |||||||
Income tax expense | 3,657 | 5,267 | (30.6) % | |||||||
Net income | 10,738 | 12,680 | (15.3) % | |||||||
Net income attributable to non-controlling interest | 256 | 428 | NM | |||||||
Net income attributable to Core Laboratories Inc. | $ | 10,482 | $ | 12,252 | (14.4) % | |||||
Diluted earnings per share | $ | 0.23 | $ | 0.26 | (11.5) % | |||||
Diluted earnings per share attributable to Core Laboratories Inc. | $ | 0.22 | $ | 0.26 | (15.4) % | |||||
Diluted weighted average common shares outstanding | 47,509 | 47,662 | (0.3) % | |||||||
Effective tax rate | 25 | % | 29 | % | NM | |||||
SEGMENT INFORMATION: | ||||||||||
Revenue: | ||||||||||
Reservoir Description | $ | 167,177 | $ | 170,513 | (2.0) % | |||||
Production Enhancement | 86,567 | 89,701 | (3.5) % | |||||||
Total | $ | 253,744 | $ | 260,214 | (2.5) % | |||||
Operating income: | ||||||||||
Reservoir Description | $ | 14,542 | $ | 18,336 | (20.7) % | |||||
Production Enhancement | 4,651 | 5,977 | (22.2) % | |||||||
Corporate and Other | 515 | 266 | NM | |||||||
Total | $ | 19,708 | $ | 24,579 | (19.8) % | |||||
"NM" means not meaningful | ||||||||||
CORE LABORATORIES INC. & SUBSIDIARIES | ||||||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||||||||
(In thousands) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
% Variance | ||||||||||||||||
ASSETS: |
|
|
| vs. Q1-25 | vs. Q4-24 | |||||||||||
Cash and cash equivalents | $ | 31,188 | $ | 22,107 | $ | 19,157 | 41.1 % | 62.8 % | ||||||||
Accounts receivable, net | 113,909 | 117,031 | 111,761 | (2.7) % | 1.9 % | |||||||||||
Inventories | 59,773 | 59,031 | 59,402 | 1.3 % | 0.6 % | |||||||||||
Other current assets | 32,807 | 30,599 | 36,286 | 7.2 % | (9.6) % | |||||||||||
Total current assets | 237,677 | 228,768 | 226,606 | 3.9 % | 4.9 % | |||||||||||
Property, plant and equipment, net | 97,927 | 97,943 | 97,063 | — % | 0.9 % | |||||||||||
Right of use assets | 55,116 | 57,490 | 56,488 | (4.1) % | (2.4) % | |||||||||||
Intangibles, goodwill and other long- | 211,391 | 207,318 | 210,249 | 2.0 % | 0.5 % | |||||||||||
Total assets | $ | 602,111 | $ | 591,519 | $ | 590,406 | 1.8 % | 2.0 % | ||||||||
LIABILITIES AND EQUITY: | ||||||||||||||||
Accounts payable | $ | 41,699 | $ | 38,497 | $ | 34,549 | 8.3 % | 20.7 % | ||||||||
Short-term operating lease liabilities | 11,508 | 11,654 | 10,690 | (1.3) % | 7.7 % | |||||||||||
Other current liabilities | 51,565 | 53,576 | 52,347 | (3.8) % | (1.5) % | |||||||||||
Total current liabilities | 104,772 | 103,727 | 97,586 | 1.0 % | 7.4 % | |||||||||||
Long-term debt, net | 124,613 | 124,367 | 126,111 | 0.2 % | (1.2) % | |||||||||||
Long-term operating lease liabilities | 42,420 | 43,981 | 43,343 | (3.5) % | (2.1) % | |||||||||||
Other long-term liabilities | 63,003 | 60,088 | 65,630 | 4.9 % | (4.0) % | |||||||||||
Total equity | 267,303 | 259,356 | 257,736 | 3.1 % | 3.7 % | |||||||||||
Total liabilities and equity | $ | 602,111 | $ | 591,519 | $ | 590,406 | 1.8 % | 2.0 % | ||||||||
CORE LABORATORIES INC. & SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(In thousands) | ||||||||
(Unaudited) | ||||||||
Six Months Ended | ||||||||
2025 | 2024 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 10,738 | $ | 12,680 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Stock-based compensation | 4,697 | 4,688 | ||||||
Depreciation and amortization | 7,387 | 7,613 | ||||||
Deferred income taxes | (3,167) | (777) | ||||||
Accounts receivable | (3,717) | (7,019) | ||||||
Inventories | (1,991) | 1,305 | ||||||
Accounts payable | 6,647 | 3,116 | ||||||
Other adjustments to net income | (11) | 1,070 | ||||||
Net cash provided by operating activities | 20,583 | 22,676 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures - operations | (6,259) | (5,918) | ||||||
Capital expenditures - rebuilding of | (1,648) | — | ||||||
Net proceeds from insurance recovery - | 4,678 | — | ||||||
Net proceeds on life insurance policies | 778 | 2,776 | ||||||
Other investing activities | 1,579 | 798 | ||||||
Net cash used in investing activities | (872) | (2,344) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (27,000) | (38,000) | ||||||
Proceeds from long-term debt | 25,000 | 22,000 | ||||||
Dividends paid | (938) | (938) | ||||||
Repurchase of common stock | (4,761) | (206) | ||||||
Equity related transaction costs and other financing activities | 19 | (613) | ||||||
Net cash used in financing activities | (7,680) | (17,757) | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 12,031 | 2,575 | ||||||
CASH AND CASH EQUIVALENTS, beginning of period | 19,157 | 15,120 | ||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 31,188 | $ | 17,695 | ||||
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income, Net Income (Loss) and Diluted Earnings (Loss) Per Share Attributable to Core Laboratories Inc. | ||||||||||||
(In thousands, except per share data) | ||||||||||||
(Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 15,291 | $ | 4,417 | $ | 16,008 | ||||||
Stock compensation (1) | — | 3,505 | — | |||||||||
Severance, inventory and asset write-downs (2) | 799 | 3,416 | — | |||||||||
Insurance recovery on property, plant and equipment (3) | (1,557) | — | — | |||||||||
Foreign exchange losses (gains) | 7 | 480 | 388 | |||||||||
Excluding specific items | $ | 14,540 | $ | 11,818 | $ | 16,396 | ||||||
Net Income (Loss) Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 10,636 | $ | (154) | $ | 9,032 | ||||||
Stock compensation (1) | — | 2,629 | — | |||||||||
Severance, inventory and asset write-downs (2) | 599 | 2,562 | — | |||||||||
Insurance recovery on property, plant and equipment (3) | (1,168) | — | — | |||||||||
Foreign exchange losses (gains) | 5 | 360 | 310 | |||||||||
Effect of higher (lower) tax rate (4) | (1,234) | 1,292 | 1,050 | |||||||||
Excluding specific items | $ | 8,838 | $ | 6,689 | $ | 10,392 | ||||||
Diluted Earnings (Loss) Per Share Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
|
|
| ||||||||||
GAAP reported | $ | 0.22 | $ | — | $ | 0.19 | ||||||
Stock compensation (1) | — | 0.05 | — | |||||||||
Severance, inventory and asset write-downs (2) | 0.01 | 0.05 | — | |||||||||
Insurance recovery on property, plant and equipment (3) | (0.02) | — | — | |||||||||
Foreign exchange losses (gains) | — | 0.01 | 0.01 | |||||||||
Effect of higher (lower) tax rate (4) | (0.02) | 0.03 | 0.02 | |||||||||
Excluding specific items | $ | 0.19 | $ | 0.14 | $ | 0.22 | ||||||
(1) Three months ended | ||||||||||||
(2) Three months ended March 31, 2025 includes severance costs, the write-down of inventory, leasehold improvements, and other exit costs associated with consolidation of certain facilities. Three months ended | ||||||||||||
(3) Three months ended | ||||||||||||
(4) Three months ended | ||||||||||||
Segment Information | ||||||||||||
(In thousands) | ||||||||||||
(Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
Reservoir | Production | Corporate and | ||||||||||
GAAP reported | $ | 12,203 | $ | 3,148 | $ | (60) | ||||||
Severance, inventory and asset write-downs | — | 799 | — | |||||||||
Insurance recovery on property, plant and equipment | (1,557) | — | — | |||||||||
Foreign exchange losses (gains) | 189 | (182) | — | |||||||||
Excluding specific items | $ | 10,835 | $ | 3,765 | $ | (60) | ||||||
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of 9.0% is defined by Bloomberg as Net Operating Profit After Tax ("NOPAT") of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures - operations. Management believes that free cash flow provides useful information to investors regarding the cash available in the period in excess of Core's needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow | |||||||||
(In thousands) | |||||||||
(Unaudited) | |||||||||
Three Months Ended | Six Months Ended | ||||||||
Net cash provided by operating activities | $ | 13,923 | $ | 20,583 | |||||
Capital expenditures - operations | (3,474) | (6,259) | |||||||
Free cash flow | $ | 10,449 | $ | 14,324 | |||||
###
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-second-quarter-2025-results-302512392.html
SOURCE Core Laboratories Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX: New Street Research sees 22% upside from proposed IPO price
- RH (RH) Tops Q1 EPS by 12c
- Shanghai Tonight opens with nearly 200 nighttime events
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Dividend, Crude Oil, OPEC, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share